Written by Emel Gerdaneri.
FDA Approves New Botox with Much Longer Duration Time
We all know that the US Food and Drug Administration (FDA) has a long and extensive approval process.
Revance's daxibotulinumtoxin A product has been waiting for this approval for a long time under its old name Daxi and its new name Daxxify.
This new neuromodulator was first reported at the end of 2020, expected to be released in 2021, but the FDA had rejected it due to "manufacturing shortfalls."
Finally, Daxxify was approved, and the aesthetic community began to enthusiastically review the new product.
Currently available neuromodulators namely Botox, Dysport, Xeomin, Jeuveau tend to last three to four months, while FDA trials suggest that Daxxify lasts for six months. It is also the first botulinum toxin approved with this duration of action.
A Cleaner Alternative
It is due to the addition of a proprietary peptide that is responsible for its long duration, allowing the Daxxify botulinum toxin to bind more effectively to the receptors minimizing muscle movement.
Also, unlike its counterparts, Daxxify does not contain human albumin, a stabilizing protein.
It's considered a vegan and even a "cleaner" alternative than Xeomin (called the "naked" toxin due to the lack of complex proteins surrounding the botulinum toxin molecule but still containing human albumin).
It will be More Expensive
Exactly how Daxxify will fit into the current portfolio of neuromodulators is not yet clear, but doctors are highlighting the fact that it will reduce patients' annual treatments.
This is a great option for those who can't or don't want to come to clinics regularly. We expect Daxxify to be a luxury product that will cost more per treatment than other neuromodulators.
Get more information about Botox
Written on 16/09/2022
Last Update: 16/09/2022